Developing and testing CD371-targeted CAR T-cells secreting IL-18 for refractory AML
Renier Brentjens, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, provides insight into the development of CAR T-cell therapy for the treatment of acute myeloid leukemia (AML), highlighting a novel armored CD371-targeted CAR T-cell product secreting interleukin-18 (IL-18) that has demonstrated robust expansion and disease clearance in a Phase I trial (NCT06017258) in patients with refractory disease. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
